

# CONTACT

**Call** 703-777-7319

Email sradkov@dbllawyers.com

# PRACTICE AREAS

Intellectual Property

# INDUSTRIES

Technology Manufacturing

### OFFICES





# **STOYAN A. RADKOV**

# OF COUNSEL

As an undergraduate, Dr. Radkov studied Microbiology graduating with the highest 1st Class BSc Honours degree in the Faculty of Animal & Microbial Sciences, University of Reading – awarded The Abbott Laboratories Prize. Ph.D. in Viral Oncology – The Ludwig Institute for Cancer Research, St Mary's Hospital – Imperial College London and a Cancer Research Campaign (CRC) funded Senior Research Fellow at Imperial College London and University College London – scientific findings published in Virology and Nature Medicine as detailed below.

After a successful career as a scientist, Dr. Radkov joined a top-tier Intellectual Property Law firm, D Young & Co, in London, where he trained as a Life Sciences Patent Attorney. He attained a Post Graduate Diploma in Intellectual Property Law from Queen Mary & Westfield, University of London & fully qualified as European Patent Attorney (EPA) – chemistry. Dr. Radkov has over 18 years of experience in international and European IP law, serving as a Global Product Attorney at Pfizer in Sandwich, England; Novartis and Syngenta Headquarters in Basel, Switzerland.

### EDUCATION

- 1st Class BSc Honors degree in the Faculty of Animal & Microbial Sciences, University of Reading
- Post Graduate Diploma in Intellectual Property Law from Queen Mary & Westfield, University of London

### ADMISSIONS

- UPC
- EPO

- EUIPO
- UKIPO

### EXPERIENCE

- Pfizer Provided patent support to the anti-viral and anti-invectives research & diagnostics teams – HCV (RNAi & Ab based therapies), HIV and Salmonella. Extensive experience in patent strategy for early and late stage research & diagnostic portfolios. IP Due Diligence (M&A, licensing opportunities etc.), FTO, Validity, Patentability & Infringement Opinions. International Licence negotiations and strategic advice
- Novartis Global Product Attorney for Galvus, Eucreas and Canakinumab. I was responsible for Due Diligence, FTO, Validity, Patentability & Infringement Opinions and work-around strategies. Patent drafting with EP & global patent prosecution.
- Syngenta Biotech EP Patent Team Lead and Global RNAi Team Lead. Providing strategic advice relating to direction of RNAi research, licensing and M&A opportunities. Responsible attorney for the M&A IP assessments as part of a global DD process for the acquisition of Devgen (value of completed deal €403million).